Announced
Completed
Synopsis
Genovis, a company that develops transfection technologies based on nanotechnology, completed the investment in SEQURNA, a biotechnology research company. Financial terms were not disclosed. "This strategic investment opens up for new product offerings to both existing and new customers, and facilitates the expansion into new application areas. We will utilize our distribution network to market and sell SEQURNA’s RNase inhibitors alongside our own catalogue of innovative tools for the biopharmaceutical and research industries," Genovis.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.